Newly onset cytopenias not always indicate a relapsing AML after allogeneic HSCT, a case of non-destructive post transplant lymphoproliferative disorder
LEUKEMIA RESEARCH REPORTS, cilt.19, 2023 (Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 19
- Basım Tarihi: 2023
- Doi Numarası: 10.1016/j.lrr.2023.100369
- Dergi Adı: LEUKEMIA RESEARCH REPORTS
- Derginin Tarandığı İndeksler: Scopus, Directory of Open Access Journals
- Anahtar Kelimeler: Acute myeloid leukemia, Post transplant lymphoproliferative disorder, Epstein-Barr virus, Rituximab
- İstanbul Medipol Üniversitesi Adresli: Evet
Özet
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains an effective option for the treatment of intermediate and high-risk Acute myeloid leukemia (AML). Post-transplant lymphoproliferative disorder (PTLD) is related to the intensity of post-transplant immunosuppression. Although Epstein-Barr virus (EBV) seropositivity and reactivation can be a major risk factor for PTLD. A few PTLDs could be EBV negative. There are a very limited number of PTLD cases following HSCT in patients with AML. We present a differential diagnosis of cytopenias after allo-HSCT. This is the first report of an AML patient developing bone marrow EBV-negative PTLD relatively late in their post-transplant course.